Our study suggests that factors such as steady state plasma Imatinib levels, MDR1 polymorphisms and ABC transporter expression influence EMR/MMR to imatinib therapy, which in turn influence FFS in patients with CP-CML. Here, ABCG2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.